Advertisement

Search Results

Advertisement



Your search for Blood matches 4665 pages

Showing 4201 - 4250


breast cancer
issues in oncology

Periodontal Disease Linked to Increased Risk of Breast Cancer in Postmenopausal Women, Especially Smokers

A large prospective study of postmenopausal women investigating an association between periodontal disease and breast cancer risk has found that among all women in the study, the risk of breast cancer was 14% higher in women who had periodontal disease. Among women who had quit smoking within the...

solid tumors

Fractionated Stereotactic Radiation More Effective Than Single-Dose Radiation in Pituitary Tumors

A recent study at Houston Methodist Hospital proved that multiple small doses of highly focused radiation therapy is safer and more effective than a single larger dose of radiation at destroying pituitary gland tumors. The findings on the use of fractionated stereotactic radiotherapy were published ...

gynecologic cancers

Access to Minimally Invasive Hysterectomies in Early Uterine Cancer Remains Persistently Limited

A new study led by Johns Hopkins researchers shows wide racial and economic disparities in access to minimally invasive hysterectomies for early uterine cancer in the United States. This is despite years of accumulating evidence that the procedures to remove the uterus are linked to fewer...

issues in oncology

Preoperative Use of Blood-Thinning Drugs Is Safe for Patients With Cancer

Among patients undergoing major cancer operations, the preoperative use of blood-thinning drugs such as heparin does not increase rates of major bleeding or transfusions, and is associated with a decreased risk of blood clots, according to new study results published by Selby et al in the Journal...

breast cancer

FDA Allows Marketing of Cooling Cap to Reduce Hair Loss During Chemotherapy

The U.S. Food and Drug Administration has cleared the first cooling cap to reduce hair loss in female breast cancer patients undergoing chemotherapy for marketing in the United States. Hair loss is a common side effect of certain types of chemotherapy, commonly associated with the treatment of...

palliative care
breast cancer
issues in oncology

SABCS 2015: Phase III BELLE-2 Trial Meets Primary Endpoint of Progression-Free Survival

Among women with locally advanced or metastatic hormone receptor–positive breast cancer that was resistant to hormone therapy, those who had mutated PIK3CA detected in their blood benefited from a combination of the investigational PI3K inhibitor buparlisib and fulvestrant (Faslodex),...

prostate cancer
issues in oncology

Repeating Abnormal PSA Tests Reduces Number of Unnecessary Biopsies

For more than 20 years, the prostate-specific antigen (PSA) test has been used to help screen for prostate cancer. However, in recent years, some task forces have called for this blood test to be abandoned because it leads to many unnecessary biopsies. Now, a new study from The Ottawa Hospital and...

breast cancer
issues in oncology

SABCS 2015: ESR1 Gene Mutations Are Associated With Worse Overall Survival in Metastatic ER-Positive Breast Cancer

A study by Chandarlapaty et al investigating whether mutations in the estrogen receptor are common in patients with advanced breast cancer and how they affect patient outcomes has found that the D538G and Y537S mutations in the estrogen receptor 1 (ESR1) gene are prevalent in patients with advanced ...

multiple myeloma

ASH 2015: Multiple Myeloma Patient Study Shows Promise for Natural Killer Cells

A first-in-human phase I study of multiple myeloma patients combined expanded cord blood-derived natural killer cells with transplantation of a patient’s own stem cells and high-dose chemotherapy, with little or none of the side effects seen with current treatments. Results from the clinical...

leukemia

ASH 2015: Young Adults With Acute Lymphoblastic Leukemia Have Encouraging Survival With Pediatric Chemotherapy Regimen

Using a pediatric chemotherapy regimen to treat young adults with acute lymphoblastic leukemia (ALL) significantly improved their outcomes compared to what has historically been achieved with “adult” treatment protocols, report Dana-Farber Cancer Institute scientists. Overall survival...

hematologic malignancies
leukemia
lymphoma
lymphoma

ASH 2015: High Response Rates, Long-Term Remissions in Relapsed/Refractory Pediatric ALL, Lymphomas After CTL019 Immunotherapy

Ninety-three percent of pediatric patients (55 of 59) with relapsed/refractory acute lymphoblastic leukemia (ALL) went into remission after receiving an investigational therapy made from their own immune cells, with continuous remissions of over 1 year in 18 patients and over 2 years in nine...

leukemia

ASH 2015: Children With Acute Lymphoblastic Leukemia Benefit From Prophylactic Antibiotics During Induction Chemotherapy

Prophylactic antibiotics significantly reduce the risk of serious bacterial infections in children during the critical first month of treatment for acute lymphoblastic leukemia (ALL), the most common childhood cancer, according to a study led by investigators from Dana-Farber/Boston Children's...

palliative care
leukemia

ASH 2015: Combination Therapy With Idelalisib Improves Progression-Free Survival vs Bendamustine/Rituximab Alone in Relapsed/Refractory CLL

In a phase III study to be presented by Zelenetz et al at the 57th American Society of Hematology Annual Meeting, idelalisib (Zydelig) plus bendamustine (Treanda) and rituximab (Rituxan), or BR, proved superior to BR alone in patients with relapsed/refractory chronic lymphocytic leukemia (CLL)...

leukemia
issues in oncology

ASH 2015: Midostaurin Improves Survival in Patients With FLT3-Mutated Acute Myeloid Leukemia Aged 18–60

A study presented by Stone et al at the 57th American Society of Hematology (ASH) Annual Meeting described a phase III trial of the first targeted therapy for genetically defined subset of patients with acute myeloid leukemia and its improvement of their survival (Abstract 6). Acute myeloid...

leukemia

ASH 2015: Researchers Identify Children Most at Risk of Overreporting Adherence to At-Home Chemotherapy Regimen

A study presented by Landier et al at the 57th American Society of Hematology (ASH) Annual Meeting examined the common problem of children in remission from acute lymphocytic leukemia (ALL) not adhering to their maintenance drug regimens, thus putting them at risk of relapse (Abstract 82). ...

supportive care

ASH 2015: Two Studies Focus on Treatment for Cancer-Associated Thrombosis

Two studies presented at the 57th American Society of Hematology (ASH) Annual Meeting examine the common problem of cancer-associated thrombosis. One looked to validate dosing guidelines for avoiding chemotherapy-induced thrombocytopenia, a common autoimmune response to therapy; the second compared ...

leukemia
issues in oncology

ASH 2015: Genetic Variants Discovered in Acute Lymphocytic Leukemia That Indicate Higher Risk for Osteonecrosis, Avascular Necrosis

Two new studies to be reported at the 57th American Society of Hematology (ASH) Annual Meeting highlighted new insights on genetic mutations in children with acute lymphocytic leukemia (ALL) that indicate a higher risk for debilitating chemotherapy-associated bone damage. The study findings were...

multiple myeloma

ASH 2015: First-in-Human Trial Using Engineered Cells to Target Multiple Myeloma Shows Early Promise

A study (Abstract LBA1) to be reported by Abbas Ali et al at the 57th American Society of Hematology (ASH) Annual Meeting demonstrated promising early outcomes of a first-in-human trial using a patient’s own genetically modified immune cells to eradicate multiple myeloma. The study...

leukemia
lymphoma
lymphoma

ASH 2015: Engineered Donor T Cells May Eradicate Progressive Disease After Stem Cell Transplant

A study (Abstract 99) to be reported today by Brudno et al at the 57th American Society of Hematology (ASH) Annual Meeting was the first clinical trial to use engineered donor immune cells to prevent progressive cancer after stem cell transplantation. The findings were presented at a...

hematologic malignancies
issues in oncology

ASH 2015: American Society of Hematology Releases Compilation of Top Choosing Wisely Recommendations Relevant to Hematology

The American Society of Hematology (ASH) has released a list of five hematology-related tests and procedures to question based on recommendations from other medical societies taking part in the American Board of Internal Medicine (ABIM) Foundation’s Choosing Wisely® campaign. This list...

hematologic malignancies
lymphoma

Prognostic Model for Survival in Advanced-Stage Mycosis Fungoides and Sézary Syndrome

As reported by Scarisbrick et al in the Journal of Clinical Oncology, a Cutaneous Lymphoma International Consortium study in a large population of patients with advanced-stage mycosis fungoides and Sézary syndrome has identified independent prognostic factors for overall survival that can be ...

issues in oncology
breast cancer

Elevated C-Reactive Protein May Be Associated With Increased Breast Cancer Risk in Postmenopausal Women Not Using Hormone Therapy

In a study reported in the Journal of the National Cancer Institute, Gunter and colleagues found that increased levels of the inflammatory marker C-reactive protein (CRP) were associated with increased risk of breast cancer in postmenopausal women not using hormone therapy. No associations of...

Chitosane-Based Injectable Biogel Delivers Anticancer Agents Directly Into Tumors in Laboratory Setting

A new, injectable “biogel” is effective in delivering anticancer agents directly into cancerous tumors and killing them, according to a study published by Monette et al in Biomaterials. The technology was developed by researchers at the University of Montreal Hospital Research Centre...

hematologic malignancies
myelodysplastic syndromes

Self-Reported Fatigue Provides Independent Prognostic Information in Patients With Myelodysplastic Syndromes

In a prospective observational cohort study reported in The Lancet Oncology, Efficace et al found that a self-reported fatigue score provides independent prognostic information on overall survival in patients with higher-risk myelodysplastic syndromes. Fatigue assessment should be included in...

gynecologic cancers
supportive care

Researchers Find Experimental Drug Reduces Ascites With Minimal Side Effects in Preclinical Studies

Women who have ovarian cancer often develop a condition called ascites, which is a buildup of fluids in the abdomen. The most common treatment for ascites is puncturing the abdomen and manually draining the fluid, which is painful, risky, and must be repeated every few weeks. University of...

prostate cancer
supportive care
integrative oncology

Yoga Helps Maintain Quality of Life, May Lessen Side Effects in Men Undergoing Prostate Cancer Treatment

Men with prostate cancer who are undergoing radiation therapy can benefit from yoga, researchers at the Perelman School of Medicine at the University of Pennsylvania reported at the Society for Integrative Oncology’s 12th International Conference. The new, first-of-its-kind study, led...

issues in oncology

Users of Smokeless Tobacco Have Higher Levels of Nicotine and Toxicant Exposure Than Cigarette Smokers

A study analyzing data from a large, nationally representative U.S. health survey population comparing biomarkers of tobacco exposure in smokeless tobacco users and cigarette smokers has found the exclusive smokeless tobacco users have higher observed levels of exposure to nicotine and a...

multiple myeloma

FDA Approves Daratumumab for Patients With Previously Treated Multiple Myeloma

Today the U.S. Food and Drug Administration granted accelerated approval for daratumumab (Darzalex) to treat patients with multiple myeloma who have received at least three prior treatments, including a proteasome inhibitor and an immunomodulatory agent, or who are double-refractory to a proteasome ...

breast cancer
issues in oncology
issues in oncology

Blood Test Detects Resistance to Aromatase Inhibitors in Breast Cancer Treatment

Scientists have developed a highly sensitive blood test that can spot when breast cancers become resistant to standard hormone treatment, and have demonstrated that this test could guide further treatment. The test gives an early warning of resistance to aromatase inhibitors, which are used to...

lymphoma

Investigational NAE Inhibitor Pevonedistat Shows Potential Activity in Patients With Relapsed/Refractory Lymphoma

A phase I study evaluating the safety, pharmacokinetic profile, pharmacodynamic effects, and antitumor activity of the first-in-class investigational NEDD8-activating enzyme (NAE) inhibitor pevonedistat (TAK-924/MLN4924) in patients with relapsed/refractory lymphoma or multiple myeloma has found...

issues in oncology

Liquid Biopsy Promotes Precision Medicine by Tracking Patient's Cancer

A team of researchers, including scientists from the Translational Genomics Research Institute (TGen), has reported that analyzing circulating tumor DNA (ctDNA) can track how a patient's cancer evolves and responds to treatment. In a study published in Nature Communications, Muhammed Murtaza, PhD, ...

prostate cancer

PARP Inhibitor Olaparib Produces High Response Rate in Metastatic Prostate Cancer With DNA Repair Defects

In a phase II trial reported in The New England Journal of Medicine, Mateo et al found that the PARP inhibitor olaparib (Lynparza) produced a high response rate in patients with previously treated metastatic castration-resistant prostate cancer with tumors exhibiting defects in DNA repair genes....

cns cancers
survivorship

Chemotherapy-Induced Hearing Loss Affects Cognition in Pediatric Brain Tumor Survivors

More children are surviving malignant brain tumors than in the past, thanks to the use of intense treatments using platinum-based chemotherapy (cisplatin and high-dose carboplatin). Unfortunately, the therapy has a known side effect of permanent hearing loss, resulting from damage to the inner ear. ...

pancreatic cancer
issues in oncology

Only 1 in 5 U.S. Patients With Pancreatic Cancer Gets Key Blood Test at Diagnosis

Only 1 in 5 patients with pancreatic cancer in the United States receives a widely available, inexpensive blood test at diagnosis that can help predict relative outcome (compared to others with the same disease stage) and guide treatment accordingly, a Mayo Clinic study showed. People who test...

breast cancer

Antiangiogenic Breast Cancer Treatment May Benefit Only Patients With Well-Perfused Tumors

A Massachusetts General Hospital (MGH) research team, in collaboration with investigators at the Dana-Farber Cancer Institute, may have found a reason why the use of antiangiogenic drugs—which has improved outcomes for patients with several types of cancer—fails to benefit some breast...

colorectal cancer
issues in oncology

Stool DNA Test Accurate in Screening for Colorectal Cancer in Alaska Native People

Cologuard stool DNA testing for colorectal cancer was found to be an accurate noninvasive screening option for Alaska Native people, a population with one of the world's highest rates of colorectal cancer, concluded researchers from the Alaska Native Tribal Health Consortium and Mayo Clinic. The...

pancreatic cancer

Immunotherapy for Pancreatic Cancer Boosts Survival by More Than 75% in Preclinical Models

A new study in mice by researchers at Fred Hutchinson Cancer Research Center has found that a specialized type of immunotherapy—even when used without chemotherapy or radiation—can boost survival from pancreatic cancer by more than 75%. The findings are promising, and human clinical...

breast cancer
issues in oncology

Exercise Could Provide a Margin of Safety for Women Who Want to Delay Preventive Mastectomy

Regular physical activity could play a role in helping women at high-risk of breast cancer delay the need for drastic preventive measures such as prophylactic mastectomy, according to new research led by the Perelman School of Medicine at the University of Pennsylvania. Results of the WISER Sister...

leukemia
issues in oncology

Reduced Relapse but No Quality-of-Life Benefit With ATRA/Arsenic Trioxide vs ATRA/Idarubicin in Acute Promyelocytic Leukemia

In a UK-based phase III trial (AML17) reported in The Lancet Oncology, Burnett et al found that a chemotherapy-free regimen of arsenic trioxide plus all-trans retinoic acid (ATRA) did not improve quality of life, the primary endpoint, vs ATRA plus idarubicin in patients with acute promyelocytic...

skin cancer

ASTRO 2015: Subset of Patients With Metastatic Melanoma Achieves Clinical Benefit From Combination of Immunotherapy and Radiation Therapy

Immunotherapy combined with palliative radiation therapy for a subset of patients with metastatic melanoma reduces the growth and spread of the cancer, according to research presented by Hiniker et al (Abstract 215) on October 20, 2015 at the American Society for Radiation Oncology’s...

lymphoma

Researchers Link Immunosuppressive Mycophenolate Mofetil to Increased Risk of Central Nervous System Lymphoma

A study led by Johns Hopkins researchers has linked the immunosuppressive drug mycophenolate mofetil to an increased risk of central nervous system lymphoma in solid organ transplant patients. But the same study also found that another class of immunosuppressive drugs, calcineurin inhibitors, given ...

issues in oncology
breast cancer
issues in oncology

Study Examines Links Between Viral and Bacterial Microbial Signatures and Triple-Negative Breast Cancer

Cancer is the result of normal cellular functions going wildly awry on a genetic level. That fact has been known for some time, but increasing evidence is showing that the human microbiome, the diverse population of microorganisms within every person, may play a key role in either setting the stage ...

leukemia

Dactinomycin Produces Durable Response in Patient With NPM1-Mutant AML

As reported by Falini et al in a letter to The New England Journal of Medicine, dactinomycin treatment resulted in morphologic and molecular complete remission ongoing at 14 months in a patient with NPM1-mutant acute myeloid leukemia (AML). NPM1-mutated AML may account for one-third of AML in...

lymphoma

Danish-Swedish Study Indicates No Survival Benefit of Routine Imaging for Diffuse Large B-Cell Lymphoma in Patients in First Complete Remission

In a Danish-Swedish population-based study reported in the Journal of Clinical Oncology, El-Galaly et al found that routine imaging for diffuse large B-cell lymphoma in patients in first complete remission does not improve post-treatment survival. Study Details The study included 525 Danish and...

hematologic malignancies
leukemia
lymphoma
issues in oncology

Half-Matched Bone Marrow Transplant Recipients May Tolerate Transplantation Just as Well as Fully Matched Recipients

Bone marrow transplantation is a lifesaving therapy for many patients with blood cancers like leukemias and lymphomas. Currently, the gold standard blood-generating stem cells are obtained from a donor, most likely a sibling, with a perfect match to the patient in order to minimize the chance of...

breast cancer
colorectal cancer
lung cancer

A Tolerant Immune System May Increase Cancer Risk

For a malignant tumor to form, cancer cells must evade the immune system's attack. Numerous studies have already shown that cancer spreads particularly aggressively if there is an unfavorable balance between suppressing and active immune cells in the tumor microenvironment. “But we didn't...

head and neck cancer
issues in oncology

Disparities in Outcomes for Children With Retinoblastoma May Suggest Unequal Access to Primary Care

Disparities in outcomes for children with retinoblastoma suggest unequal access to primary care, researchers from Dana-Farber/Boston Children's Cancer and Blood Disorders Center reported in a study published by Truong et al in JAMA Pediatrics. Although virtually all the children in the study...

lung cancer

ASCO Endorses CHEST Guideline on Treatment of Small Cell Lung Cancer

As reported in the Journal of Clinical Oncology, ASCO has endorsed the current American College of Chest Physicians (CHEST) guideline on treatment of small cell lung cancer, released in 2013. After review of evidence from an updated literature search covering 2011 to March 2015, an ASCO...

hematologic malignancies

Nonmyeloablative Transplantation With High-Dose Cyclophosphamide May Improve Outcomes in Older Patients With Hematologic Malignancy

 In a recent report of single-institution experience in the Journal of Clinical Oncology, Kasamon et al found that nonmyeloablative-related HLA-haploidentical blood or marrow transplantation (BMT) followed by high-dose cyclophosphamide produced good outcomes in patients aged 50 to 75 years...

head and neck cancer

ECC 2015: Pembrolizumab in Patients With Advanced Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Trial

Pembrolizumab (Keytruda), an anti–PD-1 therapy, may be effective as monotherapy in patients with advanced unresectable nasopharyngeal carcinoma whose tumors express programmed cell death-ligand 1 (PD-L1). Data from a phase Ib study, KEYNOTE-028, showed an overall response rate of 22.2% in 27...

Advertisement

Advertisement




Advertisement